The Patent Finder

Therapeutic Uses of Modified Relaxin Polypeptides

Ambrx, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 6 of these applications claim priority to application 13/212,101, filed Aug 17, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,452,222Nucleic Acids Encoding Modified Relaxin Polypeptides
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 10,253,083Therapeutic Uses of Modified Relaxin Polypeptides
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 10,702,588Modified Relaxin Polypeptides Comprising A Non-Naturally Encoded Amino Acid In The A Chain
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 10,751,391Methods of Treatment Using Modified Relaxin Polypeptides Comprising a Non-Naturally Encoded Amino Acid
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 11,786,578Modified Relaxin Polypeptides and Their Uses
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 9,567,386Therapeutic Uses of Modified Relaxin Polypeptides
In force
 · High confidence
Ambrx, Inc.In force
High confidence
US 11,311,605Methods of Treating Heart Failure and Fibrotic Disorders Using Modified Relaxin Polypeptides
Lapsed Apr 26, 2026 on the fee record
Ended Apr 26, 2026 · High confidence
Ambrx, Inc.Lapsed Apr 26, 2026 on the fee recordEnded Apr 26, 2026
High confidence
US 9,962,450Method of Treating Heart Failure with Modified Relaxin Polypeptides
Lapsed May 8, 2026 on the fee record
Ended May 8, 2026 · High confidence
Ambrx, Inc.Lapsed May 8, 2026 on the fee recordEnded May 8, 2026
High confidence
US 8,735,539Relaxin Polypeptides Comprising Non-Naturally Encoded Amino Acids
Lapsed May 27, 2026 on the fee record
Ended May 27, 2026 · High confidence
Ambrx, Inc.Lapsed May 27, 2026 on the fee recordEnded May 27, 2026
High confidence
US 11,439,710Nucleic Acids Encoding Modified Relaxin Polypeptides
Lapsed Sep 13, 2026 on the fee record
Ended Sep 13, 2026 · High confidence
Ambrx, Inc.Lapsed Sep 13, 2026 on the fee recordEnded Sep 13, 2026
High confidence
2 more patents in this group · Pro
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12, including 4 expired.
Upgrade to Pro
6 of these are in force and held by Ambrx, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited